The ADDF offers funding to researchers in both nonprofit and for-profit organizations for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research.
Our funding is open to:
The ADDF currently accepts grant proposals through the following RFPs. For returning grantees, we accept proposals for follow-on funding and renewals.
We provide applicants with a streamlined review process—the average time from letter of intent (LOI) decision to award decision is less than four months. For most RFPs, letters of intent are accepted and reviewed on a rolling basis during four cycles each year, corresponding to our four invited full proposal reviews.
The application deadline finish the 17th November 2017 (letter of intent); 8th Dicember 2017 (invited full proposal)
More information in the next link: ADDF Funding Opportunities
